Glucose Viaflo Baxter Médico-Farmacêutica (Glucose)

Glucose Viaflo Baxter Médico-Farmacêutica is used when rapid provision of carbohydrate energy is required, particularly in settings where oral intake is not possible or insufficient. It serves as a component of parenteral nutrition regimens and can be employed for immediate correction of low blood glucose levels.

• Management of hypoglycemia in patients unable to take oral glucose.
• Supplementation of carbohydrate calories in total parenteral nutrition formulations.
• Fluid replacement therapy when combined with electrolytes and vitamins.
• Support during perioperative periods to maintain plasma glucose stability.
• Treatment of metabolic demands in critically ill or trauma patients.

Intravenous administration of glucose may be associated with a range of physiological responses, most of which are predictable and dose‑related.

Common

• Transient hyperglycemia that resolves with metabolic clearance.
• Mild irritation or pain at the injection site.
• Electrolyte shifts, particularly decreased serum potassium.
• Fluid overload in patients receiving large volumes.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypoglycemia if glucose infusion is abruptly discontinued.
• Allergic or anaphylactic reaction to the solution components.
• Hyperosmolar hyperglycemic state in susceptible individuals.

Before initiating therapy with Glucose Viaflo Baxter Médico-Farmacêutica, clinicians should evaluate patient-specific factors and monitor relevant clinical parameters to minimize risks.

• Assess baseline blood glucose and adjust infusion rate accordingly.
• Monitor serum electrolytes, especially potassium and sodium, during treatment.
• Use caution in patients with renal or cardiac insufficiency due to fluid volume concerns.
• Avoid rapid infusion in neonates and infants to prevent metabolic disturbances.
• Review concomitant insulin therapy to prevent extreme glucose fluctuations.
• Ensure sterility; discard any solution that appears cloudy or discolored.

Glucose solutions can interact with other intravenous agents or systemic medications, influencing glucose metabolism or fluid balance.

Avoid

• Concurrent high‑dose insulin infusions without appropriate glucose supplementation.
• Co‑administration with other hypertonic dextrose solutions, which may cause excessive osmolar load.
• Simultaneous infusion of potassium chloride in concentrations that could precipitate in the line.

Use with caution

• Patients receiving diuretics, as fluid shifts may affect glucose concentration.
• Medications that affect renal glucose handling, such as SGLT2 inhibitors.
• Catecholamine or glucocorticoid therapy, which can increase endogenous glucose production.